柳鞅
Lv2
140 积分
2021-09-26 加入
-
A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer’s Disease
2天前
已完结
-
Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases
22天前
已完结
-
Lineage-specific intolerance to oncogenic drivers restricts histological transformation
2个月前
已完结
-
Role of NLRP3 Inflammasome in Stroke Pathobiology: Current Therapeutic Avenues and Future Perspective
2个月前
已完结
-
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
3个月前
已完结
-
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
3个月前
已完结
-
LncRNA CHKB-DT Downregulation Enhances Dilated Cardiomyopathy Through ALDH2
3个月前
已完结
-
Pharmaceutical profiling method for lipophilicity and integrity using liquid chromatography–mass spectrometry
3个月前
已完结
-
An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential
4个月前
已完结
-
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
4个月前
已完结